The clinical spectrum of labile hypertension: a management dilemma

Controversies in Hypertension VI: Paroxysmal Hypertension

Paroxysmal hypertension is characterized by a sudden and significant increase in blood pressure that may have coexisting hyperadrenergic symptoms (headache, palpitations, diaphoresis) with or without an obvious precipitating cause. Pheochromocytoma is suggested, although less than 1% of such patients have the tumor. Four syndromes should be considered, including labile hypertension, panic attacks, pseudopheochromocytoma, and baroreflex failure. Labile hypertension includes paroxysms that are provoked by obvious stress or anxiety; they may be asymptomatic or have hyperadrenergic symptoms. Similarly, panic attacks are precipitated by fear or anxiety. Pseudopheochromocytoma is characterized by paroxysms without obvious precipitating stress or anxiety, although anxiety may result from the paroxysm, and the paroxysms are invariably symptomatic; abnormal repression of emotions underlies most cases. Afferent baroreflex failure presents as symptomatic hypertensive paroxysms often precipitated by emotional or environmental stress alternating with periods of frank hypotension; orthostatic hypotension frequently coexists. No guidelines specify therapy of paroxysmal hypertension and no randomized controlled trials with hard endpoints exist for this syndrome. We discuss in detail the four pheochromocytoma mimics in the differential diagnosis of paroxysmal hypertension with recommendations on diagnosis and therapy.

Wearable Blood Pressure Monitoring Devices: Understanding Heterogeneity in Design and Evaluation

OBJECTIVE

Rapid advances in cuffless blood pressure (BP) monitoring have the potential to radically transform clinical care for cardiovascular health. However, due to the large heterogeneity in device design and evaluation, it is difficult to critically and quantitatively evaluate research progress. In this two-part manuscript, we provide a principled way of describing and accounting for heterogeneity in device and study design.

METHODS

We first provide an overview of foundational elements and design principles of three critical aspects: 1) sensors and systems, 2) pre-processing and feature extraction, and 3) BP estimation algorithms. Then, we critically analyze the state-of-the-art methods via a systematic review.

RESULTS

First, we find large heterogeneity in study designs, making fair comparisons extremely challenging. Moreover, many study designs have data leakage and are underpowered. We suggest a first open-contribution BP estimation benchmark for standardization. Next, we observe that BP distribution in the study sample and the time between calibration and test in emerging personalized devices confound BP estimation error. We suggest accounting for these using a convenient metric coined "explained deviation". Finally, we complement this manuscript with a website, https://wearablebp.github.io, containing a bibliography, meta-analysis results, datasets, and benchmarks, providing a timely plaWorm to understand state-of-the-art devices.

CONCLUSION

There is large heterogeneity in device and study design, which should be carefully accounted for when designing, comparing, and contrasting studies.

SIGNIFICANCE

Our findings will allow readers to parse out the heterogeneous literature and move toward promising directions for safer and more reliable devices in clinical practice and beyond.

Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients

BACKGROUND

Hypertension management in older patients represents a challenge, particularly when hospitalized.

OBJECTIVE

The objective of this study is to investigate the determinants and related outcomes of antihypertensive drug prescription in a cohort of older hospitalized patients.

METHODS

A total of 5671 patients from REPOSI (a prospective multicentre observational register of older Italian in-patients from internal medicine or geriatric wards) were considered; 4377 (77.2%) were hypertensive. Minimum treatment (MT) for hypertension was defined according to the 2018 ESC guidelines [an angiotensin-converting-enzyme-inhibitor (ACE-I) or an angiotensin-receptor-blocker (ARB) with a calcium-channel-blocker (CCB) and/or a thiazide diuretic; if >80 years old, an ACE-I or ARB or CCB or thiazide diuretic]. Determinants of MT discontinuation at discharge were assessed. Study outcomes were any cause rehospitalization/all cause death, all-cause death, cardiovascular (CV) hospitalization/death, CV death, non-CV death, evaluated according to the presence of MT at discharge.

RESULTS

Hypertensive patients were older than normotensives, with a more impaired functional status, higher burden of comorbidity and polypharmacy. A total of 2233 patients were on MT at admission, 1766 were on MT at discharge. Discontinuation of MT was associated with the presence of comorbidities (lower odds for diabetes, higher odds for chronic kidney disease and dementia). An adjusted multivariable logistic regression analysis showed that MT for hypertension at discharge was associated with lower risk of all-cause death, all-cause death/hospitalization, CV death, CV death/hospitalization and non-CV death.

CONCLUSIONS

Guidelines-suggested MT for hypertension at discharge is associated with a lower risk of adverse clinical outcomes. Nevertheless, changes in antihypertensive treatment still occur in a significant proportion of older hospitalized patients.

Estimating cardiovascular health gains from eradicating indoor cold in Australia

BACKGROUND

Exposure to cold indoor temperature (< 18 degrees Celsius) increases cardiovascular disease (CVD) risk and has been identified by the WHO as a source of unhealthy housing. While warming homes has the potential to reduce CVD risk, the reduction in disease burden is not known. We simulated the population health gains from reduced CVD burden if the temperature in all Australian cold homes was permanently raised from their assumed average temperature of 16 degrees Celsius to 20 degrees Celsius.

METHODS

The health effect of eradicating cold housing through reductions in CVD was simulated using proportional multistate lifetable model. The model sourced CVD burden and epidemiological data from Australian and Global Burden of Disease studies. The prevalence of cold housing in Australia was estimated from the Australian Housing Conditions Survey. The effect of cold indoor temperature on blood pressure (and in turn stroke and coronary heart disease) was estimated from published research.

RESULTS

Eradication of exposure to indoor cold could achieve a gain of undiscounted one and a half weeks of additional health life per person alive in 2016 (base-year) in cold housing through CVD alone. This equates to 0.447 (uncertainty interval: 0.064, 1.34; 3% discount rate) HALYs per 1,000 persons over remainder of their lives through CVD reduction. Eight percent of the total health gains are achievable between 2016 and 2035. Although seemingly modest, the gains outperform currently recommended CVD interventions including persistent dietary advice for adults 5-9% 5 yr CVD risk (0.017 per 1000 people, UI: 0.01, 0.027) and persistent lifestyle program for adults 5-9% 5 yr CVD risk (0.024, UI: 0.01, 0.027).

CONCLUSION

Cardiovascular health gains alone achievable through eradication of cold housing are comparable with real-life lifestyle and dietary interventions. The potential health gains are even greater given cold housing eradication will also improve respiratory and mental health in addition to cardiovascular disease.

Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective

There are currently, 3 generations of beta-adrenergic blockers for the treatment of hypertension and cardiovascular diseases. The 1^st generation caused vasoconstriction and bronchoconstriction due to β₁ + β₂ receptor blockade and unopposed α₁ receptors. The 2^nd generation of beta-blockers has lesser adverse effects than the 1^st generation with the 3^rd generation beta-blockers having much lesser effects than the other two generations. Current US and International guideline do not recommend beta-blockers as first line therapy of hypertension, but only in the presence of coronary artery disease or heart failure due to their lesser antihypertensive effect. These recommendations are disputed by several older and recent studies which have shown that the beta-blockers are effective and safe for the treatment of hypertension and could be used as first line therapy. To clarify this issue a Medline search of the English language literature was conducted between 2012 and 2021 and 30 pertinent papers were selected. The data from these studies show that the beta-blockers have inferior antihypertensive and stroke protective effect compared with the other classes of antihypertensive drugs and should be used as first line therapy only in patients with hypertension associated with coronary artery disease or heart failure. The information from these papers and collateral literature will be discussed in this perspective.

Pseudopheochromocytoma: an Uncommon Cause of Severe Hypertension

PURPOSE OF REVIEW

Pseudopheochromocytoma or paroxysmal hypertension is an underrecognized condition that requires a thorough investigation of secondary causes of hypertension. In this review, we aim to provide an overview of pathogenesis, clinical manifestations, biochemical evaluation, and potential therapeutic options to manage patients with pseudopheochromocytoma.

RECENT FINDINGS

The pathogenesis of this condition has not been completely elucidated but certain patients show overactivity of the sympathetic nervous system and present with elevated epinephrine and dopamine levels. Workup should include a proper evaluation of blood pressure in distinct clinical scenarios, including ambulatory blood pressure monitoring. Management should be focused on treatment of acute hypertensive episodes and prevention of paroxysms. Treatment of patients with pseudopheochromocytoma should be individualized. Psychopharmacotherapy and psychotherapeutic interventions play an important role in controlling patients' symptoms.

Pseudopheochromocytoma

Pseudopheochromocytoma manifests as severe, symptomatic paroxysmal hypertension without significant elevation in catecholamine and metanephrine levels and lack of evidence of tumor in the adrenal gland. The clinical manifestations are similar but not identical to those in excess circulating catecholamines. The underlying symptomatic mechanism includes augmented cardiovascular responsiveness to catecholamines alongside heightened sympathetic nervous stimulation. The psychological characteristics are probably attributed to the component of repressed emotions related to a past traumatic episode or repressive coping style. Successful management can be achieved by strong collaboration between a hypertension specialist and a psychiatrist or psychologist with expertise in cognitive-behavioral panic management.

Labile hypertension: a new disease or a variability phenomenon?

Blood pressure (BP) is a physiological parameter with short- and long-term variability caused by complex interactions between intrinsic cardiovascular (CV) mechanisms and extrinsic environmental and behavioral factors. Available evidence suggests that not only mean BP values are important, but also BP variability (BPV) might contribute to CV events. Labile hypertension (HTN) is referred to sudden rises in BP and it seems to be linked with unfavorable outcomes. The aim of this article was to review and summarize recent evidence on BPV phenomenon, unraveling the labile HTN concept along with the prognostic value of these conditions.

Direct means of obtaining CAVI0-a corrected cardio-ankle vascular stiffness index (CAVI)-from conventional CAVI measurements or their underlying variables

OBJECTIVE

Cardio-ankle vascular index (CAVI) as measured using the VaSera device (CAVI_VS, Fukuda Denshi), has been proposed as a stiffness index that does not depend on blood pressure. We have recently shown theoretically that CAVI_VS still exhibits blood pressure dependence, and proposed the corrected index CAVI₀. The present study aims to establish a method of calculating [Formula: see text] either (i) from VaSera-reported values of cardiac-brachial and brachial-ankle pulse transit times (tb and tba, respectively) and blood pressure, or (ii) directly from CAVI_VS. To derive this method, the relationship among CAVI_VS and its scale constants a and b, tb, tba, and blood pressure has to be established.

APPROACH

From data of 497 subjects, eight candidate CAVI parameters were defined and calculated, containing all combinations of left or right tb/tba/blood pressure. Candidates were evaluated through correlation with measured left and right CAVI_VS. Correlations were compared statistically. Once the correct candidates were determined, two constants (a and b) required for converting CAVI_VS to CAVI₀ were estimated through linear regression.

MAIN RESULTS

Left and right CAVI_VS are calculated using left and right tba; however, both left and right CAVI_VS are calculated using right brachial blood pressures and right tb. Constants a and b for conversion of CAVI_VS to CAVI₀ were estimated to be 0.842 [0.836 0.848] and 0.753 [0.721 0.786] (mean [95%CI]), respectively. Equations to estimate CAVI₀ from CAVI_VS, and to directly calculate CAVI₀ from the VaSera output are provided in this paper, as well as in a directly usable spreadsheet supplement.

SIGNIFICANCE

Our results permit straightforward calculation of [Formula: see text] during a study, as well as retrospective estimation of [Formula: see text] from CAVI_VS in already published studies or where the original transit time values are not available, paving the way for thorough comparison of CAVI₀ to CAVI_VS in clinical and research settings. Novelty and significance Cardio-ankle vascular index (CAVI) as measured using the VaSera device (CAVI_VS, Fukuda Denshi), has been proposed as a blood pressure-independent arterial stiffness index. We have recently shown theoretically that CAVI_VS still exhibits pressure dependence, and proposed a corrected index, CAVI₀. In the present study, we derived equations to directly obtain CAVI₀ using data from the VaSera device. Our results permit straightforward calculation of [Formula: see text] during a study, as well as retrospective estimation of [Formula: see text] from CAVI_VS in already published studies, paving the way for thorough comparison of CAVI₀ to CAVI_VS in clinical and research settings.

Labile and Paroxysmal Hypertension: Common Clinical Dilemmas in Need of Treatment Studies

Although "labile hypertension" is regularly encountered by clinicians, there is a paucity of information available to guide therapeutic decisions. This review discusses its clinical relevance, the limitations of current knowledge, and possible directions for future research and clinical management. Results of studies that assessed measures of blood pressure variability or reactivity are reviewed. The limited information about effects of antihypertensive drugs on blood pressure variability is discussed. Two different clinical presentations are differentiated: labile hypertension and paroxysmal hypertension. Labile hypertension remains a clinical impression without defined criteria or treatment guidance. Paroxysmal hypertension, also called pseudopheochromocytoma, presents as dramatic episodes of abrupt and severe blood pressure elevation. The disorder can be disabling. Although it regularly raises suspicion of a pheochromocytoma, such a tumor is found in <2 % of patients. The cause, which involves both emotional factors and the sympathetic nervous system, and treatment approaches, are presented.

Arterial stiffness evaluated by cardio-ankle vascular index (CAVI) in adolescent hypertension

Elevated blood pressure (BP) is a major risk factor for atherosclerosis. As the studies concerning vascular alterations in pediatric patients are rare, we aimed to study the relationship between hypertension and arterial stiffness in adolescence by novel method independent from BP during examination. Twenty nonobese adolescent boys (16.5 ± 0.4 years) with newly diagnosed essential hypertension, 20 adolescent boys (16.7 ± 0.4 years) with newly diagnosed white-coat hypertension, and 20 healthy controls matched to age and body mass index were examined. Cardio-ankle vascular index (CAVI), brachial-ankle pulse wave velocity (baPWV), pre-ejection period (PEP), and ejection time (ET) were evaluated. CAVI was significantly increased in essential hypertension patients compared with controls (p < 0.05) with no significant difference in white-coat hypertension patients. Significantly higher baPWV was found in essential and white-coat hypertension patients compared with controls (both p < 0.001). White-coat hypertension patients showed significantly shortened PEP and ET compared with controls (p < 0.01 and p < 0.001, respectively) and essential hypertension patients (both p < 0.05). For the first time, the arterial stiffness in adolescents with newly diagnosed essential and white-coat hypertension was studied using BP-independent index CAVI combined with conventional baPWV. Our study revealed significantly increased CAVI in adolescents with newly diagnosed essential hypertension compared with controls. Our findings could help to understand hypertension-atherosclerosis interaction.